Checkpoint Therapeutics’ cosibelimab could become the ninth PD-(L)1 drug to reach the US market, but who will be around to launch it?
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
The latest edition of the PD(L)anner provides key updates and details upcoming global events in immuno-oncology.
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.